- Home
- OPRX vs ARMP Comparison
OPRX vs ARMP Comparison
Compare OPRX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRX
- ARMP
- Stock Information
- Founded
- OPRX 2006
- ARMP N/A
- Country
- OPRX United States
- ARMP United States
- Employees
- OPRX N/A
- ARMP N/A
- Industry
- OPRX Business Services
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPRX Consumer Discretionary
- ARMP Health Care
- Exchange
- OPRX Nasdaq
- ARMP Nasdaq
- Market Cap
- OPRX 154.0M
- ARMP 52.1M
- IPO Year
- OPRX N/A
- ARMP N/A
- Fundamental
- Price
- OPRX $8.72
- ARMP $1.42
- Analyst Decision
- OPRX Buy
- ARMP Strong Buy
- Analyst Count
- OPRX 8
- ARMP 1
- Target Price
- OPRX $9.06
- ARMP $7.00
- AVG Volume (30 Days)
- OPRX 231.5K
- ARMP 24.1K
- Earning Date
- OPRX 05-12-2025
- ARMP 05-06-2025
- Dividend Yield
- OPRX N/A
- ARMP N/A
- EPS Growth
- OPRX N/A
- ARMP N/A
- EPS
- OPRX N/A
- ARMP N/A
- Revenue
- OPRX $92,127,000.00
- ARMP $5,174,000.00
- Revenue This Year
- OPRX $12.12
- ARMP $8.43
- Revenue Next Year
- OPRX $10.87
- ARMP N/A
- P/E Ratio
- OPRX N/A
- ARMP N/A
- Revenue Growth
- OPRX 28.81
- ARMP 14.24
- 52 Week Low
- OPRX $3.78
- ARMP $0.90
- 52 Week High
- OPRX $14.13
- ARMP $3.45
- Technical
- Relative Strength Index (RSI)
- OPRX 54.56
- ARMP 51.42
- Support Level
- OPRX $8.09
- ARMP $1.25
- Resistance Level
- OPRX $8.92
- ARMP $1.43
- Average True Range (ATR)
- OPRX 0.64
- ARMP 0.12
- MACD
- OPRX -0.07
- ARMP 0.06
- Stochastic Oscillator
- OPRX 69.34
- ARMP 98.11
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.